Amryt Pharma plc

Financial performance has remained strong, with revenue growing from $54.83M in Q4 2021 to $61.13M in Q3 2022. Gross profit continued to perform well, with margins at 45% in the latest quarter. Operating income reached -$10.46M in Q3 2022, holding a steady -17% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $6.52M. Net income dropped to -$20.80M, keeping EPS at -$0.32. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.